🍽️ vinpocetine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cerebral Blood Flow: Vinpocetine is believed to enhance cerebral blood flow by acting as a vasodilator and improving microcirculation in the brain. This increased blood flow may potentially enhance oxygen and nutrient delivery to brain cells, supporting cognitive function and overall brain health.

  2. Neuroprotection: Vinpocetine has been studied for its potential neuroprotective effects, particularly in conditions associated with cerebral ischemia or reduced blood flow to the brain. It may help protect neurons from damage caused by ischemia, hypoxia, or neurotoxicity, thereby preserving cognitive function and reducing the risk of neurodegenerative diseases.

  3. Cognitive Enhancement: Some studies suggest that vinpocetine may have cognitive-enhancing effects, including improvements in memory, attention, and executive function. These effects are thought to be mediated by its ability to enhance cerebral blood flow, increase glucose utilization in the brain, and modulate neurotransmitter activity.

  4. Antioxidant Activity: Vinpocetine exhibits antioxidant properties, which may help reduce oxidative stress and inflammation in the brain. By scavenging free radicals and inhibiting oxidative damage to cellular components, vinpocetine may contribute to neuroprotection and cognitive health.

  5. Anti-inflammatory Effects: Vinpocetine has been reported to possess anti-inflammatory properties, which could be beneficial in mitigating neuroinflammation and associated neurodegenerative processes. By suppressing inflammatory signaling pathways and cytokine production, vinpocetine may help protect against neuronal injury and cognitive decline.

  6. Clinical Applications: Vinpocetine is used clinically in some countries for the treatment of cerebrovascular disorders, cognitive impairment, and age-related cognitive decline. It may also be prescribed as an adjunctive therapy in the management of conditions such as stroke, vascular dementia, and Alzheimer's disease.

  7. Safety and Tolerability: Vinpocetine is generally well-tolerated when used at recommended doses. Common side effects may include gastrointestinal disturbances, headache, dizziness, and flushing. Rare adverse effects such as hypotension, arrhythmias, and allergic reactions have been reported with high doses or prolonged use.

  8. Drug Interactions: Vinpocetine may interact with certain medications, particularly those affecting blood clotting or platelet function. Caution is advised when combining vinpocetine with anticoagulants, antiplatelet agents, or drugs that affect hemostasis to avoid the risk of bleeding or hemorrhage.

  9. Regulatory Status: The regulatory status of vinpocetine varies by country. In some regions, it is available as a dietary supplement or over-the-counter medication, while in others, it is classified as a prescription drug. Consultation with a healthcare professional is recommended before initiating vinpocetine therapy to ensure appropriate use and monitoring.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations    |     πŸ“ Dosage Seen

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of vinpocetine,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by vinpocetine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Clostridioides genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Clostridium genus Decreases 👪 Source Study Pathogen
Roseburia genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Ruminococcus genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Enterocloster genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Collinsella aerofaciens species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Roseburia intestinalis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Coprococcus comes species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Dorea formicigenerans species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bifidobacterium adolescentis species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Parabacteroides distasonis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of vinpocetine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0.2 -0.2
ADHD 2.9 0.3 8.67
Age-Related Macular Degeneration and Glaucoma 0.7 0 0
Allergic Rhinitis (Hay Fever) 1.6 0.8 1
Allergies 4.4 1.7 1.59
Allergy to milk products 1.1 0.4 1.75
Alopecia (Hair Loss) 1.2 1.2
Alzheimer's disease 2.5 4.6 -0.84
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.2 1.3 1.46
Ankylosing spondylitis 2.1 1.2 0.75
Anorexia Nervosa 0 2.3 0
Antiphospholipid syndrome (APS) 1.9 0.1 18
Asthma 0.6 2 -2.33
Atherosclerosis 0.7 2.2 -2.14
Atrial fibrillation 2.4 0.8 2
Autism 7.4 7.6 -0.03
Barrett esophagus cancer 0.2 0 0
benign prostatic hyperplasia 0.2 0.2
Bipolar Disorder 0.7 1 -0.43
Brain Trauma 0.6 0.7 -0.17
Cancer (General) 2.1 -2.1
Carcinoma 2 1.7 0.18
Celiac Disease 1.6 2.5 -0.56
Cerebral Palsy 1.2 1.2 0
Chronic Fatigue Syndrome 4.1 5.3 -0.29
Chronic Kidney Disease 1.2 2.3 -0.92
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 0.3 1 -2.33
Chronic Urticaria (Hives) 1.2 1.4 -0.17
Coagulation / Micro clot triggering bacteria 0.6 0.9 -0.5
Colorectal Cancer 2.2 1 1.2
Constipation 1.4 0.9 0.56
Coronary artery disease 1.6 1 0.6
COVID-19 7.9 11.2 -0.42
Crohn's Disease 6.2 5 0.24
cystic fibrosis 0.5 0.9 -0.8
deep vein thrombosis 0.5 0.5 0
Depression 5.6 7.6 -0.36
Dermatomyositis 0 0.2 0
Eczema 1 1.3 -0.3
Endometriosis 2.1 0.5 3.2
Eosinophilic Esophagitis 0.2 -0.2
Epilepsy 2.5 2.4 0.04
Fibromyalgia 1.8 2.3 -0.28
Functional constipation / chronic idiopathic constipation 4.6 2.8 0.64
gallstone disease (gsd) 1.6 0.6 1.67
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.5 0.9 0.67
Generalized anxiety disorder 1.6 1.5 0.07
giant cell arteritis 0.4 -0.4
Glioblastoma 0 0
Gout 0.3 -0.3
Graves' disease 0.9 1.6 -0.78
Halitosis 0.5 0 0
Hashimoto's thyroiditis 2 0.5 3
Hidradenitis Suppurativa 0.1 0.2 -1
Histamine Issues 2.7 1.2 1.25
hypercholesterolemia (High Cholesterol) 0.4 0.8 -1
hyperglycemia 0.2 2.2 -10
Hyperlipidemia (High Blood Fats) 1 0.5 1
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 1.6 3.3 -1.06
Hypothyroidism 0.9 -0.9
Hypoxia 0.8 0.8
IgA nephropathy (IgAN) 3.5 -3.5
Inflammatory Bowel Disease 2.8 7.7 -1.75
Insomnia 0.7 0.9 -0.29
Intelligence 1.5 1.5
Intracranial aneurysms 0.8 0.5 0.6
Irritable Bowel Syndrome 4.1 4.1 0
Liver Cirrhosis 3.4 2.7 0.26
Long COVID 6.2 6.9 -0.11
Low bone mineral density 1 -1
Lung Cancer 0.7 1.6 -1.29
Mast Cell Issues / mastitis 0.2 0.6 -2
ME/CFS with IBS 0.5 2.5 -4
ME/CFS without IBS 1.3 1.3 0
Menopause 1 1
Metabolic Syndrome 6.7 6.7 0
Mood Disorders 8.6 7.6 0.13
multiple chemical sensitivity [MCS] 0.7 0.4 0.75
Multiple Sclerosis 2.7 4 -0.48
Multiple system atrophy (MSA) 1.3 0.6 1.17
neuropathic pain 1 -1
Neuropathy (all types) 0.9 0.2 3.5
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.8 4.6 -1.56
NonCeliac Gluten Sensitivity 0.2 -0.2
Obesity 6.3 3.4 0.85
obsessive-compulsive disorder 5.7 3.4 0.68
Osteoarthritis 1.6 0.1 15
Osteoporosis 1.2 1.6 -0.33
pancreatic cancer 0 0
Parkinson's Disease 2.7 3.7 -0.37
Polycystic ovary syndrome 2.2 1.6 0.38
Postural orthostatic tachycardia syndrome 0.4 0.5 -0.25
Premenstrual dysphoric disorder 1 0 0
primary biliary cholangitis 0.3 1.2 -3
Psoriasis 4.1 2 1.05
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 5 3.2 0.56
Rosacea 0.2 0.9 -3.5
Schizophrenia 5.6 1.9 1.95
scoliosis 0.3 0.6 -1
Sjögren syndrome 1.2 2.7 -1.25
Sleep Apnea 1 1.5 -0.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.4 0.3 0.33
Stress / posttraumatic stress disorder 2.4 2.5 -0.04
Systemic Lupus Erythematosus 2.8 1.3 1.15
Tic Disorder 0.8 0.9 -0.13
Tourette syndrome 0.4 0.3 0.33
Type 1 Diabetes 3.3 2.2 0.5
Type 2 Diabetes 7 7 0
Ulcerative colitis 2.1 5 -1.38
Unhealthy Ageing 3.9 2.2 0.77

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.222.64 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.222.64 ]